News
BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $84 from $87 and keeps a Buy rating on the shares. While Q1 ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback